AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11777716
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate ophthalmic suspension 0.5%
Trial: 9651632
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine 1
Trial: 9651632
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine 2
Trial: 8016555
Drug: 2.2 mM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 mM CHX mouthrinses used twice daily
Trial: 8016555
Drug: 11.9 mM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.9 mM NaF rinses used daily
Trial: 8016555
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CHX and NaF rinses
Trial: 30253197
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vortioxetine
Trial: 30253197
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vortioxetine
Trial: 23199977
Drug: Inhaled procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled procaterol before exercise
Trial: 23199977
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhaled procaterol)
Trial: 20391086
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued daily life)
Trial: 18795931
Drug: Patch Test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch Test with MDBGN
Trial: 18795931
Drug: Accumulated ROAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accumulated ROAT doses (1, 2, and 3 weeks) with MDBGN
Trial: 4076354
Drug: Daily structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily structured physical exercise for 10 weeks
Trial: 4076354
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily inspiratory muscle training by resistive breathing for 10 weeks
Trial: 4076354
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo training for 10 weeks
Trial: 29428926
Drug: Articulatory costal
RxNorm normalized name: Coastal Water-hyssop Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulatory costal manual therapy (AC group)
Trial: 29428926
Drug: Neurolymphatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurolymphatic therapy (NL group)
Trial: 29428926
Drug: Articulatory spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulatory spinal manual therapy (AS group)
Trial: 22137666
Drug: Once‐per‐week EPO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐per‐week EPO, 1200 U/kg/dose, subcutaneously for 4 weeks
Trial: 22137666
Drug: 3‐times‐a‐week EPO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐times‐a‐week EPO, 400 U/kg/dose, subcutaneously for 4 weeks
Trial: 15650312
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 60 mg twice daily (bid)
Trial: 11291084
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of synthetic mutant ras peptides with granulocyte-macrophage colony-stimulating factor as adjuvant
Trial: 9384020
Drug: Aerosolized oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized oxygen with antibacterial, antiphlogistic drugs, expectorants, antispastic and antiasthmatic drugs
Trial: 9384020
Drug: Convenient simple
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convenient simple aerosolized oxygen inhalation
Trial: 8202964
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 to 40 mg/d) for 3 and 6 weeks
Trial: 2239815
Drug: Yomeishu (YMS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yomeishu (YMS) 20 ml twice a day before meals for 12 weeks
Trial: 1093464
Drug: Dimethyl sulfoxide
RxNorm normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dimethyl sulfoxide therapy (DAT)
Trial: 27805571
Drug: Intravenous peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous peramivir 800 mg once a day for 6 days
Trial: 27805571
Drug: Intravenous peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous peramivir 400 mg twice daily for 6 days
Trial: 26114120
Drug: Weight Achievement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week intensive program for diabetes weight management
Trial: 23102873
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BTA injection).
Trial: 11240959
Drug: Atopy patch
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopy patch test (APT) combined with specific IgE measurement
Trial: 11240959
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of positive APT results and specific IgE measurement
Trial: 28049642
Drug: Clofarabine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (10 mg/m2 on days 1-5 of each of both cycles)
Trial: 25982338
Drug: Propranolol combined
RxNorm normalized name: propranolol and other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol combined with oral prednisolone for the initial 2 weeks
Trial: 23063625
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine plus triamcinolone 40mg IA injection
Trial: 21750266
Drug: ALA (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA (1,800 mg/day) for 2 weeks
Trial: 21750266
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion with ALA pretreatment
Trial: 21750266
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion without ALA pretreatment
Trial: 19401659
Drug: Propofol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.2 mg kg(‐1) bolus, followed by infusion at 2 mg kg(‐1) h(‐1))
Trial: 19401659
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC, infusion at 5 mg kg(‐1) h(‐1))
Trial: 15290395
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment (Control)
Trial: 11894980
Drug: Oral combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combined continuous hormone replacement therapy (HRT) with Kliogest (oestradiol 2 mg, norethisterone 1 mg)
Trial: 9469797
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg perindopril administered at 0900 h
Trial: 9469797
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg perindopril administered at 2100 h
Trial: 3074777
Drug: Danazol 200
RxNorm normalized name: danazol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 200 mg twice a day
Trial: 28545321
Drug: Intranasal MLV
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal MLV vaccine (containing BoHV-1, BRSV, BPIV-3)
Trial: 28545321
Drug: Subcutaneous MLV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous MLV vaccine (containing BVDV-1, BVDV-2, BoHV-1, BRSV, BPIV-3)
Trial: 28545321
Drug: Intranasal MLV
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal MLV vaccine
Trial: 23062631
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% permethrin cream and a comprehensive scabies control programme including hygiene monitoring and health education classes.
Trial: 21906391
Drug: amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (5 mg/day)
Trial: 26577506
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Trial: 3883767
Drug: Nifedipine in
RxNorm normalized name: nifedipine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine in cardioplegic solution (average dose 407 +/- 22 micrograms at one center; 476 +/- 22 micrograms at another center)
Trial: 29471930
Drug: Methadone Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone Maintenance Treatment (MMT)
Trial: 29149381
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education programme (DTTP) for conventional insulin therapy in outpatient group
Trial: 29149381
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education programme (DTTP) for conventional insulin therapy in inpatient group
Trial: 19037084
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg QD
Trial: 19037084
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg BID
Trial: 19037084
Drug: Lisinopril 40
RxNorm normalized name: lisinopril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 40 mg QD
Trial: 17959549
Drug: Bronchovaxom treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchovaxom treatment (3.5 mg daily for 10 days every month for 3 months)
Trial: 17959549
Drug: Budesonide aerosol
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aerosol (200 microg once or twice daily for 3 months)
Trial: 17959549
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment group (budesonide)
Trial: 15547426
Drug: Bilateral electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral electrical stimulation with Nucleus 24 cochlear implant
Trial: 9551877
Drug: 4-day oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day oral salt load (150 mmol NaCl extra per day)
Trial: 1833903
Drug: Enoximone therapy
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone therapy
Trial: 6315447
Drug: Natural and
RxNorm normalized name: Natural and artifical flavoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural and synthetic oestrogen administration
Trial: 25046547
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd)
Trial: 25046547
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/qd)
Trial: 22269042
Drug: DHA-containing functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-containing functional food (300 mg DHA, 92 kcal) consumed an average of 5 days/week from 24 weeks gestation until delivery
Trial: 20201608
Drug: Ethinylestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE) 30 microg/DRSP 3 mg (n = 573)
Trial: 20201608
Drug: Ethinylestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE) 30 microg/DRSP 3 mg
Trial: 18684735
Drug: Recombinant follicle‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle‐stimulating hormone (rFSH) 150 IU
Trial: 15844695
Drug: HCl infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCl infusion
Trial: 7845419
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of miconazole 55 mg/g denture lacquer (single application)
Trial: 7845419
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available miconazole 2% gel (applied four times daily for 2 weeks)
Trial: 2840035
Drug: Tegafur 600
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur 600 mg p.o. for 8 weeks followed by 4 weeks rest (4 courses)
Trial: 27647222
Drug: Dose-dense TCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense TCF regimen with 30% dose reduction
Trial: 27647222
Drug: Dose-dense TCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense TCF regimen without dose reduction
Trial: 24820281
Drug: Pregabalin combined
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin combined with intrathecal sufentanil infusion
Trial: 24820281
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with intrathecal sufentanil infusion
Trial: 24820281
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine sulfate controlled‐release tablet
Trial: 20804445
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg + metformin XR
Trial: 20804445
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + metformin XR
Trial: 18404537
Drug: Ascorbate pre-treatment
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbate pre-treatment
Trial: 10641162
Drug: Ciprofloxacin beta-cyclodextrin
RxNorm normalized name: Sulfobutylether-beta-cyclodextrin
DrugBank: Sulfobutylether-beta-cyclodextrin (DB18607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin beta-cyclodextrin inclusion complex dental implants
Trial: 8890721
Drug: Intranasal GH
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GH 0.05 IU/kg
Trial: 8890721
Drug: Intranasal GH
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GH 0.10 IU/kg
Trial: 8890721
Drug: Intranasal GH
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GH 0.20 IU/kg
Trial: 8890721
Drug: Subcutaneous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GH 0.10 IU/kg
Trial: 8890721
Drug: Intravenous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GH 0.015 IU/kg
Trial: 3937598
Drug: CP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP (cyclophosphamide 1 g/m2 plus cisplatin 60 mg/m2)
Trial: 3937598
Drug: HCAP (hexamethylmelamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCAP (hexamethylmelamine 150 mg/m2/day X 7, cyclophosphamide 400 mg/m2, doxorubicin 30 mg/m2, and cisplatin 60 mg/m2)
Trial: 20507398
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg loading dose at week 0 followed by adalimumab 40 mg eow starting at week 2
Trial: 20507398
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg eow
Trial: 10204812
Drug: Bed rest,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bed rest, diet control, and antihypertensive drug (control group)
Trial: 7491697
Drug: BT563 (anti-CD25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (anti-CD25 mAb), cyclosporine, and steroids
Trial: 7491697
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and cyclosporine-steroids
Trial: 7364141
Drug: Betnovate cream
RxNorm normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betnovate cream (betamethasone 17‐valerate 0.1%)
Trial: 28338208
Drug: CBCT technology
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBCT technology combined with conventional root canal therapy (control group)
Trial: 21299274
Drug: Telephone-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive behavioral therapy (T-CBT) for 16 sessions over 20 weeks
Trial: 21299274
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual through the CBOC
Trial: 16732839
Drug: SQ sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SQ sumatriptan 6 mg
Trial: 16732839
Drug: TMB 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMB 200 mg and DPH 25 mg (TMB/DPH)
Trial: 15616486
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic eye drops, a pacifier, plus three doses of 24% sucrose
Trial: 15616486
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic eye drops, a pacifier, plus three doses of sterile water
Trial: 8985627
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% timolol gel
Trial: 8985627
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release acetazolamide
Trial: 2888417
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine (MST 30)
Trial: 2888417
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg lormetazepam (Noctamid)
Trial: 22527424
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical imiquimod cream
Trial: 22527424
Drug: Post-imiquimod therapy
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-imiquimod therapy (antibiotic creams, topical steroids, emollients)
Trial: 18347392
Drug: Racol (omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racol (omega-3 fatty acid-containing diet) at a maximum dose of 600 mL/day during CRT
Trial: 12749508
Drug: Repaglinide 1
RxNorm normalized name: repaglinide 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 1 mg/d
Trial: 12749508
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 mg/d
Trial: 29282469
Drug: Esketamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (all doses combined)
Trial: 25158897
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 5 ml (25 mg/ml) tranexamic acid (TXA) and 5 ml analgesic containing epinephrine (3 μg/ml) injected at several points into the posterior capsule before installation of the prosthesis; 10 ml TXA and 10 ml analgesic containing epinephrine injected into the periosteum, synovium, joint capsule, tendons, and deep fascia before tourniquet release; TXA solution (20 ml) injected into the articular cavity after wound closure; drainage tube clamped for 4 h.
Trial: 25158897
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Injection of analgesic containing epinephrine into soft tissue, control of active bleeding, and clamping of the drainage tube for 4 h only.
Trial: 24654216
Drug: Methylphenidate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (25 mg daily)
Trial: 7985255
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of terbutaline (2, 4, and 6 mg)
Trial: 2532229
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (40 micrograms three times daily)
Trial: 2532229
Drug: Fenoterol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.2 mg three times daily)